Prevention and treatment progress of paronychia caused by epidermal growth factor receptor tyrosine kinase inhibitors
10.3760/cma.j.cn114015-20240402-00212
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂致甲沟炎的预防和治疗研究进展
- Author:
Tong SUN
1
;
Feng LIU
;
Honglian ZHANG
Author Information
1. 山东省招远市人民医院药剂科，烟台 265400
- Publication Type:Journal Article
- Keywords:
Receptor, epidermal growth factor;
Receptor protein-tyrosine kinases;
Enzyme inhibitors;
Non-small cell lung cancer;
Paronychia;
Skin;
Adverse drug reaction
- From:
Adverse Drug Reactions Journal
2024;26(11):689-694
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor tyrosine kinase inhibitors (EGRF-TKIs) were standard therapeutic agents for advanced non-small cell lung cancer with positive EGFR mutations, most of these drugs could cause paronychia with various severity. EGFR-TKIs caused paronychia and periungual suppurative inflammation mainly through their pharmacological effects, which usually occurred 4 to 12 weeks after medication. The paronychia caused by EGFR-TKIs was manifested as acute paronychia firstly, and then might develop into purulent granuloma. The diagnosis of paronychia could base on the patient′s medical history, clinical symptoms, clinical examinations, and medication situation. Currently, there was no standard scheme to prevent and treat paronychia induced by EGFR-TKIs. The relatively effective measures included controlling risk factors, adjusting the regimen of EGFR-TKIs, using β-blockers, antibacterial drugs, local glucocorticoids and Chinese herbal medicines, etc. Severe paronychia could also be treated through surgical intervention.
